AP2000001977A0 - The process for manufacturing topical opthalmic preparations without systemic effects. - Google Patents
The process for manufacturing topical opthalmic preparations without systemic effects.Info
- Publication number
- AP2000001977A0 AP2000001977A0 APAP/P/2000/001977A AP2000001977A AP2000001977A0 AP 2000001977 A0 AP2000001977 A0 AP 2000001977A0 AP 2000001977 A AP2000001977 A AP 2000001977A AP 2000001977 A0 AP2000001977 A0 AP 2000001977A0
- Authority
- AP
- ARIPO
- Prior art keywords
- topical
- systemic
- preparations
- timolol
- clonidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
For treating eye diseases, various kinds of medications are used. They are used in form of topical preparations or in form of systemic preparations to be taken orally or parenterally. Of topical preparations some are for topical use only e.g. framycetin, neomycin, loteprednol ebanoate, etc. However, large majority of topical ophthalmic drugs are for systemic use also, e.g.. Ciprofloxacin, gentamicin, timolol, clonidine, dexamethasone, betamethasone, carbachol, etc. Some of these drugs when used topically are also found to have systemic effects and if they are of serious nature limits the use of that drug, e.G. cardiopulmonary effects of b-blockers like timolol. Dryness of mouth, flush, fever, tachy cardia, urinary retention, convulsion irritability with atropine. Hypertension with phenylephine. Increased alivation, nausea, vomiting, diarrhea, stomach cramps, bronchial secretions, bronchial constriction, asthma, bradycardia, paresthesia with miotics, hypotension with clonidine. Dry mouth, fatigue and drowsiness with apraclonidine and brimonidine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN90BO1999 IN185228B (en) | 1999-02-03 | 1999-02-03 | |
| PCT/IN2000/000008 WO2000049990A2 (en) | 1999-02-03 | 2000-02-02 | The process for manufacturing topical ophthalmic preparations without systemic effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AP2000001977A0 true AP2000001977A0 (en) | 2000-12-31 |
Family
ID=11077485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/2000/001977A AP2000001977A0 (en) | 1999-02-03 | 2000-02-02 | The process for manufacturing topical opthalmic preparations without systemic effects. |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1139970A2 (en) |
| AP (1) | AP2000001977A0 (en) |
| AU (1) | AU4429100A (en) |
| BR (1) | BR0004530A (en) |
| CA (1) | CA2326690A1 (en) |
| EA (1) | EA200000918A1 (en) |
| ID (1) | ID28121A (en) |
| IL (1) | IL138824A0 (en) |
| IN (1) | IN185228B (en) |
| WO (1) | WO2000049990A2 (en) |
| ZA (1) | ZA200006252B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8858961B2 (en) | 2000-07-14 | 2014-10-14 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| AU2005220199B2 (en) * | 2000-07-14 | 2007-03-08 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
| NZ521185A (en) * | 2000-07-14 | 2005-02-25 | Allergan Inc | Compositions containing alpha-2-adrenergic agonist components |
| DE10132876A1 (en) * | 2001-07-06 | 2003-01-30 | Medproject Pharma Entwicklungs | Two-phase, drop-onable hydrogels for use on the eye |
| US7439241B2 (en) | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| ES2647618T3 (en) | 2004-05-25 | 2017-12-22 | Galderma Pharma S.A. | Compounds, formulations and procedures to treat or prevent inflammatory skin disorders |
| EP2329849B1 (en) | 2009-11-18 | 2015-04-29 | Galderma Research & Development | Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder |
| FR2977493B1 (en) | 2011-07-05 | 2014-02-14 | Galderma Res & Dev | NOVEL STABLE ANESTHETIC COMPOSITION FOR REDUCING SKIN REACTIONS |
| WO2014127243A1 (en) | 2013-02-15 | 2014-08-21 | Allergan, Inc. | Sustained drug delivery implant |
| WO2014150899A1 (en) * | 2013-03-15 | 2014-09-25 | Chapin Matthew J | Topical ophthalmic formulations for treating migraine |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US11382909B2 (en) | 2014-09-05 | 2022-07-12 | Sydnexis, Inc. | Ophthalmic composition |
| US11052094B2 (en) | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| GB202110420D0 (en) * | 2021-07-20 | 2021-09-01 | Rosemont Pharmaceuticals Ltd | Liquid pharmaceutical composition of clonidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6056684B2 (en) * | 1977-11-07 | 1985-12-11 | 東興薬品工業株式会社 | eye drops |
| DD294174A5 (en) * | 1990-05-04 | 1991-09-26 | Sigrid Keipert | OPHTHALMIKA WITH RESET EFFECT AND A NEW PROCESS FOR THEIR MANUFACTURE |
| FR2678832B1 (en) * | 1991-07-10 | 1995-03-17 | Europhta Sa Laboratoire | NOVEL OPHTHALMIC COMPOSITIONS WITH IMPROVED RESORPTION AND METHODS OF PREPARING THE SAME. |
| FR2679773A1 (en) * | 1991-07-30 | 1993-02-05 | Merck Sharp & Dohme | Ophthalmic preparation containing an acceptable antimicrobial osmotic agent |
| DE19614823A1 (en) * | 1996-04-15 | 1997-10-16 | Mann Gerhard Chem Pharm Fab | Ophthalmic composition with prolonged retention time on the eye |
-
1999
- 1999-02-03 IN IN90BO1999 patent/IN185228B/en unknown
-
2000
- 2000-02-02 AP APAP/P/2000/001977A patent/AP2000001977A0/en unknown
- 2000-02-02 ID IDW20002252A patent/ID28121A/en unknown
- 2000-02-02 EP EP00925571A patent/EP1139970A2/en not_active Withdrawn
- 2000-02-02 AU AU44291/00A patent/AU4429100A/en not_active Abandoned
- 2000-02-02 IL IL13882400A patent/IL138824A0/en unknown
- 2000-02-02 CA CA002326690A patent/CA2326690A1/en not_active Abandoned
- 2000-02-02 EA EA200000918A patent/EA200000918A1/en unknown
- 2000-02-02 WO PCT/IN2000/000008 patent/WO2000049990A2/en not_active Application Discontinuation
- 2000-02-02 BR BR0004530-6A patent/BR0004530A/en active Pending
- 2000-11-01 ZA ZA200006252A patent/ZA200006252B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN185228B (en) | 2000-12-09 |
| WO2000049990A3 (en) | 2001-07-26 |
| AU4429100A (en) | 2000-09-14 |
| ZA200006252B (en) | 2001-11-29 |
| EA200000918A1 (en) | 2001-10-22 |
| IL138824A0 (en) | 2001-10-31 |
| ID28121A (en) | 2001-05-03 |
| EP1139970A2 (en) | 2001-10-10 |
| WO2000049990A2 (en) | 2000-08-31 |
| BR0004530A (en) | 2001-04-03 |
| CA2326690A1 (en) | 2000-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2000001977A0 (en) | The process for manufacturing topical opthalmic preparations without systemic effects. | |
| WO2004071469A3 (en) | Methods of administering a dermatological agent to a subject | |
| US9216167B2 (en) | Ketorolac tromethamine compositions for treating or preventing ocular pain | |
| AU2003301747A1 (en) | Pharmaceutical compositions suitable for the treatment of ophthalmic diseases | |
| MXPA05008140A (en) | A rapid-acting pharmaceutical composition. | |
| CA2460140A1 (en) | Compositions for treatment of common cold | |
| BR0313575A (en) | Method of transdermal transport of topically administered pharmaceutical products, vehicle, vehicle composition, pharmaceutical composition and use of one or more phosphate derivative complexes of lipophilic pharmaceutically acceptable compounds with other excipients | |
| WO2006093784A3 (en) | Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents | |
| AU2001288460A1 (en) | Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| BR0305628A (en) | Pharmaceutical composition for treating sexual dysfunction in a mammal comprising peptide and its use | |
| El Maalouf et al. | Could we expect to improve survival in small cell lung cancer? | |
| Blijham et al. | Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study | |
| US6444676B1 (en) | Use of PARP inhibitors in the treatment of glaucoma | |
| CA2310950A1 (en) | An efficacious dosage regiment of galantamine that reduces side effects | |
| WO2005011618A3 (en) | Methods for the treatment of male and female sexual dysfunction | |
| AU2003290015A1 (en) | Mastitis treatment | |
| WO2004080414A3 (en) | Composition and method for treating inflammations by reducing c-reactive protein | |
| WO2001041747A3 (en) | Pharmaceutical preparation containing cytostatic agents and electron acceptors for treating cancer | |
| WO2003047697A3 (en) | Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer | |
| MX2022013391A (en) | Dosage regimen for the treatment of cancer. | |
| US20010025027A1 (en) | Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation | |
| WO2004030623A3 (en) | Nitroxide radioprotector formulations and methods of use | |
| WO2006098754A3 (en) | A suspension comprising an active principle, a suspending vehicle, a density-modifying solid with an increased physical stability | |
| WO2000061171A3 (en) | Uses of mammalian ox2 protein and related reagents |